← Back to Search

Imaging

CCTA for Heart Health in Prostate Cancer Patients

N/A
Recruiting
Led By Suparna C. Clasen, MD, MSCE
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 months, and 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at a heart scan (CCTA) for prostate cancer patients on hormone therapy (ADT) to check for blocked arteries.

Who is the study for?
Men over 40 with prostate cancer who are starting or already on androgen deprivation therapy (ADT) for more than a year can join. They must have at least one risk factor for artery disease like high blood pressure, high cholesterol, diabetes, or tobacco use but no current heart symptoms.
What is being tested?
The study is testing if using Coronary CT Angiography (CCTA), a special type of imaging scan that looks at the arteries in the heart, is better than usual care in spotting heart vessel problems in men undergoing ADT for prostate cancer.
What are the potential side effects?
CCTA may involve exposure to radiation and contrast dye which can cause allergic reactions or kidney issues. Usual care has no additional side effects beyond standard medical practice.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 months, and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 months, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Atherosclerosis in CCTA Arm
Proportion of Subjects Eligible for Treatment Based on Automated Plaque Assessment from CCTA
Secondary study objectives
Reduction in atherosclerotic cardiovascular disease (ASCVD) risk score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CCTA GroupExperimental Treatment1 Intervention
Group II: Usual Care GroupActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Myovant Sciences GmbHIndustry Sponsor
22 Previous Clinical Trials
12,362 Total Patients Enrolled
5 Trials studying Prostate Cancer
4,540 Patients Enrolled for Prostate Cancer
National Comprehensive Cancer NetworkNETWORK
120 Previous Clinical Trials
7,300 Total Patients Enrolled
6 Trials studying Prostate Cancer
334 Patients Enrolled for Prostate Cancer
Sumitomo Pharmaceuticals AmericaIndustry Sponsor
4 Previous Clinical Trials
203 Total Patients Enrolled
1 Trials studying Prostate Cancer
33 Patients Enrolled for Prostate Cancer
Indiana UniversityLead Sponsor
1,044 Previous Clinical Trials
1,316,769 Total Patients Enrolled
8 Trials studying Prostate Cancer
553 Patients Enrolled for Prostate Cancer
PfizerIndustry Sponsor
4,675 Previous Clinical Trials
28,717,129 Total Patients Enrolled
43 Trials studying Prostate Cancer
12,843 Patients Enrolled for Prostate Cancer
Suparna C. Clasen, MD, MSCEPrincipal InvestigatorIndiana University

Media Library

Coronary CT Angiography (CCTA) (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT05879913 — N/A
Prostate Cancer Research Study Groups: CCTA Group, Usual Care Group
Prostate Cancer Clinical Trial 2023: Coronary CT Angiography (CCTA) Highlights & Side Effects. Trial Name: NCT05879913 — N/A
Coronary CT Angiography (CCTA) (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05879913 — N/A
~48 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top